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Abstract 
Scaffolds are implants used to deliver cells, drugs, and genes into the body in a local 
controlled release pattern which offers many advantages over systematic drug delivery.  
Composite scaffolds of polyvinyl alcohol (PVA) and quaternary bioactive glass (46S6 
system) with different ratios of glass contents were prepared by lyophilisation technique.  
The broad spectrum antibiotic ciprofloxacin (Cip) was impregnated to the scaffold during 
the fabrication in a concentration of 5, 10 and 20%.  Biodegradation rate and in-vitro 
mineralization of the prepared scaffolds were performed by soaking the scaffolds in 
simulated body fluid (SBF). Phase identification, microstructure, porosity, bioactivity, 
mechanical properties and drug release pattern in PBS were characterized by XRD, SEM 
coupled with EDS, Hg-porosimeter, inductively coupled plasma-optical emission 
spectroscopy (ICP-OES), universal testing machine, fourier transform infrared (FTIR)  
and UV-spectrophotometer, respectively.  A porous scaffold has been obtained with 
porosity up to 85%. By increasing the glass contents in the prepared scaffold the porosity 
and the degradation rate decrease however, the compressive strength was enhanced. A 
sustained drug release pattern was observed with a quasi-Fickian diffusion mechanism. 
The formulated ciprofloxacin loaded porous polyvinyl alcohol scaffold gave an 
acceptable physicochemical properties and was able to deliver the drug in a prolonged 
release pattern which offers a distinguish treatment for osteomylitis as well as local 
antibacterial effect. 
 
Keywords: Tissue engineering, scaffolds, ciprofloxacin, drug release, freeze drying, 
polyvinyl alcohol.  
   
 
2 
 
1. Introduction  
 Due to the increasing in population, there is a clinical demand for engineerined 
bone tissue. Tissue engineering is a promising field of bone repair and regenerative 
medicine in which cultured cells, scaffolds and osteogenic inductive signals are used to 
regenerate tissues. One of the present challenges in tissue engineering is the development 
of suitable scaffold materials that can be used as templates for cell adhesion, growth and 
proliferation [1]. Microorganisms that enter bone structures by spreading from the 
bloodstream or surrounding tissues or by direct contamination during trauma or surgery 
causes osteomyelitis [2]. A chronic osteomyelitis treatment protocol combines both 
surgical removing of dead bone tissue and prolonged parenteral or oral antimicrobial 
therapy [3–6]. The efficiency of systemic antimicrobial therapy is limited by poor drug 
accumulation in bone tissue, an impaired local immune response, and changes in bacterial 
growth rate, biofilm formation and intracellular location of the pathogens [4, 5]. Thus 
systemic treatment should be continued for at least six weeks, which causes important 
side effects and makes patient compliance difficult [6]. The production of implantable 
devices able to provide high levels of antimicrobial agents for a prolonged time at the 
infection site and with low level of side effects may improve the efficacy/safety ratio of 
the therapeutic strategies [7, 8]. 
Bioactive glass has many applications in bone tissue engineering, because of its known 
ability to bond strongly to bone and promote bone growth upon in vivo implantation [9]. 
When implanted in the body, bioactive glass induces an interfacial bioactive response. By 
contrast, in-vitro, it has been documented that the ionic products from the dissolution of 
the bioactive glass actually enhance osteoblast attachment, proliferation, differentiation 
and mineralization [10-12], as well as induce the differentiation of bone marrow stromal 
cells into mature extracellular producing osteoblasts [13]. Furthermore, the dissolution 
products of bioactive glass exert control over genetic factors of bone growth [14]. 
Nevertheless, bioactive glass, as compared to cortical and cancellous bone forms, tends to 
have weaker mechanical properties, especially in porous form. This fact restricts the use 
of these materials in a wide range of applications.  
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One approach to enhancing the mechanical properties of materials is the elaboration of 
inorganic–organic composites, as they often show an excellent combination between 
strength and toughness, as well as improved characteristics, when compared to their 
individual components. 
Bioactive scaffolds were able to provide a three dimensional (3-D) architecture for 
enhancing osteogenesis and angiogenesis. Most of the scaffolds were built on complex 
constructs of several composition and additives. Natural polymer such as chitosan, 
alginate or gelatin [15-17] or synthetic polymer such as poly lactic acid (PLA), poly 
glycolic acid(PGA) an poly lactic –co-glycolic acid (PLGA) are widely used for polymer 
scaffold. However, some drawbacks still exist upon using polymers including: formation 
of acidic species, this leads to a decrease in pH and tissue inflammation [18, 19]. Among 
several choices of polymers, poly (vinyl alcohol) (PVA), a hydrophilic semicrystalline 
polymer, has been frequently explored as an implant material in wide array of biomedical 
applications such as drug delivery systems, wound dressings, membranes, surgical repairs 
and artificial skin, mainly due to its excellent mechanical strength, biocompatibility, and 
nontoxicity [15, 16].   
Direct application of antibiotics or growth factors to the defect site and the control release 
of the drug delivery systems have been developed [20, 21]. Antibiotics can be 
incorporated into bone substitutes [22]. The sustained release of antibiotics from scaffold 
structures has been widely demonstrated to control the kinetic of the release [23]. Drug 
releasing polymer scaffolds should have certain criteria such as a homogeneity of the 
drug distribution, good binding affinity of the drug to the scaffold, define amount of the 
drug loading as well as release kinetic and stability [23-25]. The most widely acceptable 
agents in local delivery system for chronic osteomylitis are amino glycosis and 
quinolones.  Ciprofloxacin (1-cyclopropyl-6-fluro-1, 4-dihydro-4-oxo-7- (1-pipera 
Zinyl)-3- quinoline carboxylic acid) is a fluroquinolone derivative, widely used in 
osteomyelitis because of its favorable penetration and bactericidal effect on all the 
probable osteomyelitis pathogens [29]. The main purpose of the current study was to 
develop and fabricate a construct of bioactive scaffold combining an antibiotic 
(ciprofloxacin). Bioactive glass powders were used as powder fillers to reinforce poly 
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vinyl alcohol scaffold. Characterization of these scaffolds before and after addition of the 
drug has been investigated by TEM, XRD, FTIR, mercury prosimeter, SEM coupled with 
EDS, ICP-OES, universal testing machine and UV-spectrophotometer. Bioactivity of the 
composite scaffolds and their use as drug carriers to effectively deliver therapeutic agent 
in a sustained and controlled manner has been studied.  
  
2. Materials and methods 
2.1. Fabrication of PVA/SG-B –Cip scaffolds 
46S6 bioactive glass powder was synthesized by sol-gel method SG-B as following. 
A colloidal solution of 46S6 was prepared by sol-gel. Initially, 56 ml of tetraethoxysilane 
(TEOS:Fluka, Mwt=208.33) was added to 350 ml of distilled water and 350 ml of 
ethanol at room temperature . pH was adjusted at 2 by nitric acid with continuous stirring 
for 1hr, addition of 24.5 g of calcium nitrate hydrate (Fluka, Mwt=236) to the above 
solution continue stirring till dissolving, addition of 21.07 g of sodium hydroxide (Prolab, 
Mwt= 40) to the above mixture (the previous mixture was named solution A), 10 g of 
polyethylene glycol (PEG-Fluka Mwt=600) was dissolved in 400 ml of distillate water at 
room temperature. 3.43 g of ammonium dihydrogen phosphate (MERK, Mwt=115.03) 
was added to the PEG solution, this mixture was named solution B. Furthermore, solution 
(B) was gradually added on solution (A) with continuous stirring over night. The resulted 
solution was filtrated and washed with distillate water for 3 times and with ethanol for 1 
time using centrifuge with 1650 rpm for 10 min drying of the washed gel at 70
º
C for 
overnight. The dried powder was calcinied at 600
ο
C for 2hr. 
 
2.1.1. Composite preparation     
PVA/SG-B-Cip composite scaffolds were prepared by employing freeze drying technique 
as demonstrated in figure (1.1). Firstly, PVA (ALDRICH, Mwt= 67.000) was dissolved 
in distilled water at 80
o
C for 2hr using a polymer concentration of 15 wt%. Three 
different concentrations of SG-B (nano particles see TEM image figure (1.2)) 33.5,50 and 
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66.5 wt%, were added to the PVA solution and continue stirred for overnight using a 
magnetic stirrer in order to break the SG-B agglomerates and ensure a better 
(homogenous) distribution of SG-B particles in the composite scaffolds. Three different 
concentrations of ciprofloxacin 5, 10 and 20 wt% were added to the above mixture 
continue stirred for 1hr (scaffolds with the same composition was prepared without drug 
loading as a control). Scaffolds were casted in Teflon molds and kept at -18
o
C for 
overnight, and freeze dried for 24 hr then the scaffolds were removed from the molds and 
kept in the desecrator for further analysis as mentioned below.     
 
2.2. Morphological and microstructural properties 
The microarchitecture of these scaffolds was assessed qualitatively using scanning 
electron microscopy (SEM) and quantitatively using mercury intrusion porosimetry 
(MIP) and liquid displacement method. 
 
2.2.1. SEM  
SEM analyses were performed on a thin piece of scaffold sheared from the center using a 
sharp razor blade after soaking in liquid nitrogen for 2 minutes. Scaffolds were observed 
using (max. of 20 kV) SEM with gold palladium coating to avoid beam damage of the 
polymer, which can be prominent on these scaffolds that have very fine microstructure. 
 
2.2.2. MIP 
MIP was performed using (PORESIZER 9320 V2.08) to determine median pore 
diameter, and percent porosity.  
 
2.2.3. Liquid displacement method 
Scaffold samples were submersed in cyclohexan for 1 hr. The volume of a scaffold 
immersed in the fluid is equal to the volume of the displaced fluid, and we can calculate 
the porosity from the following equation:                      
P % = [(W1-W3)/ (W2-W3)] x100                                     (1) 
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Where W1: weight of the scaffold before immersion, W2: weight of the scaffold after 
immersion and W3: weight after drying by this method we can just get the porosity 
percentage (P %). 
 
2.3. Mechanical properties of the prepared scaffolds 
Bones are often submitted to compression stress in the body. It has been broadly accepted 
by the research community to perform compression assays for evaluating biomaterials for 
potential use as bone repair. For that reason, the mechanical behavior of the composites 
was evaluated by compression tests. Specimens were evenly cut from the most 
homogeneous region of the foam to form blocks measuring 10 × 10 × 10mm
3
. These 
samples were positioned between parallel plates using equipment EMIC DL 3000 and 
compressed with a crosshead speed of 0.5mm·min
−1
 and a 1.0 kN load cell. At least three 
samples (n = 3) of each hybrid system were measured and the results averaged. 
Compressive strength tests were carried out to determine the effect of bioactive glass and 
the drug concentrations on the mechanical strength of scaffolds. 
 
2.4. Bioactivity  
2.4.1. Phase analysis by X-ray diffraction (XRD). 
X-ray diffraction (XRD) technique (PhilipsX’Pert-MPD system with a CuKa wavelength 
of 1.5418A°) was used to analyze the structure of the prepared SG-B and PVA/ SG-B 
composite scaffolds. The diffract meter was operated at 40kV and 30mA at a 2ɵ range of 
10–70°employing a step size of 0.058/s. 
 
2.4.2. Infrared studies 
Fourier transformed infrared analysis (FTIR; Nicolet Magna-IR 550 spectrometer, 
Madison, Wisconsin) was performed to identify the nature of the chemical bonds 
between atoms. The samples were small pellets, of 0.5 cm diameter, obtained by pressing 
the scaffolds powder with KBr. 
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2.4.3. SEM coupled with EDS 
The morphology of surfaces of scaffolds was studied by using scanning electron 
microscopy (SEM) (Jeol JSM 6301). It is a technique of morphological analysis based on 
the principle of electron-matter interactions. To allow surface conduction, the scaffolds 
were metalized by gold-palladium layer (a few µm of thickness) before being introduced 
into the analysis room. Semi quantitative chemical analysis on scaffolds surfaces after 
immersion in SBF, covered by gold-palladium layer to allow surface conduction, was 
performed by energy dispersive spectroscopy (EDS) in Jeol JSM 6400. 
 
2.4.4. ICP-OES 
The concentrations of (Ca, p and Si) elements after each soaking time in SBF were 
measured by using Inductively Coupled Plasma-Optical - Emission Spectrometry (ICP-
OES). This method offers a high sensitivity, less than 1µg/g depending on the analyzed 
matrix and offers a high accuracy. The principle is based on the determination of the 
amount of each element present in solution by analyzing the intensity of the radiation 
emitted at the specific elemental frequency after the nebulisation of atoms. 
 
2.5. In vitro degradation studies 
The degradation pattern of the composite scaffold was studied in PBS medium at 37 ◦C. 
groups of scaffolds (3 scaffolds in each) were immersed in PBS and incubated for up to 
30 days. After each period time one of the scaffolds was washed two times by distilled 
water to remove ions adsorbed on the surface and was dried. Initial weight of the scaffold 
was noted as Wo and dry weight as Wt. The degradation of scaffolds was calculated 
using the following formula: 
Degradation % = (Wo – Wt)/Wo × 100                             (2) 
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2.6. Ciprofloxacin release behavior 
Drug incorporation into the scaffolds was investigated by means of XRD, FTIR and SEM 
coupled with EDS.  
 
Phosphate buffer solution (PBS), pH 7.4 (10 ml), previously heated at 37
⁰
C, was added to 
test tubes containing freshly prepared scaffolds. The tubes were kept at 37
⁰
C with shaking 
(50 oscillations min
-1
) and, at pre-established times, 1 ml samples of the release medium 
were taken and the drug concentration was determined spectrophotometrically  at 277 nm 
(Jenway 6705 UV/Vis, UK). The samples were replaced with fresh buffer in order to 
keep constant volume of medium. All experiments were carried out in triplicate. 
Ciprofloxacin release was monitored for 360 hr.   
 
2.7. Mechanism of ciprofloxacin release 
Korsmeyer–Peppas model [31] was used to find out the mechanism of drug release from 
the investigated scaffolds: 
Mt/ M∞= Ktn                                                                  (3) 
Where, Mt / M∞ is fraction of drug released at time t, k is the rate constant and n is the 
release exponent. In case of quasi-Fickian diffusion the value of n < 0.5, Fickian 
diffusion n =0.5, non-Fickain or anomalus transport n =0.5-1.0 and Case II transport n = 
1.0. 
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3. Results and discussion  
3.1. Morphological and microstructural properties 
The effect of the particle size of SG-B particles on the properties of PVA/SG-B scaffolds, 
which are being developed for tissue engineering applications [32].  The morphology of 
the prepared scaffolds is presented in (figure 2); in which we can observe that all the 
prepared scaffolds have wide range of interconnected pores including macro, micro and 
nanopores as it also confirmed by mercury porosimeter. PVA scaffold shows highly 
interconnected pores with smooth pore walls. Incorporation of ciprofloxacin into the 
PVA scaffold changes the arraying and shapes of pores and its thickness due to the 
interaction between ciprofloxacin and PVA.   As the glass content increases the porosity 
decreases and the pore walls becomes thicker. Among several processing techniques, the 
freeze drying method was chosen since it could provide easy control of the pore structure 
[33]. The co-existence of macropores and micropores is not only favorable for the 
ingrowth of cells and new tissue but also beneficial to the exchange of nutrients and 
metabolic waste [34]. The porosity percentage for the prepared scaffolds was determined 
by MIP and liquid displacement methods and there was no significant difference between 
the two methods as it is demonstrated in table (1) [32]. 
      
3.2. Mechanical properties  
The mechanical behavior of the prepared scaffolds was characterized by determining the 
compressive strength. The PVA alone exhibit low compressive strength as shown in 
figure (3). In the produced scaffolds, a marked change could be observed, as the amount 
of glass and drug increased the compressive strength increase. The incorporation of SG-B 
into PVA polymer enhances the compressive strength, due to their small particle size and 
large surface area which results in great attachment of SG-B particles to the polymer 
matrix as reported before [33-38]. 
 
3.3. Bioactivity 
Figures (4) and figure (5) represent XRD and FTIR respectably of the prepared PVA/SG-
B composite scaffolds with SG-B and PVA as references before immersion in SBF.  
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3.3.1.1. X-ray diffraction analysis and FTIR before immersion in SBF 
The X-ray diffraction analysis result from the pure bioactive glass is as expected it did 
not show the presence of any crystalline phase, being totally amorphous. On the other 
hand, the XRD patterns from both samples of pure PVA and composite scaffolds have 
shown some diffraction bands. Hence, it has being identified as a semi-crystalline 
structure due to the superior concentration of hydroxyls groups.  The XRD curve for 
PVA/SG-B can be directly verified the sum up of both contributions from PVA with 
semi-crystalline structure and amorphous phase of SG-B [39]. It can be noted for two 
peaks for PVA/SG-B at 2θ of 26.6◦ (113) and 33.64◦ (131), which indicated some degree 
of crystallinity on the biopolymer network which diminish with increase of the glass 
content. That would be a typical XRD pattern for the scaffold showing contribution from 
all components in the system [40, 41]. 
The contribution of each and every component on the final produced scaffold network 
was confirmed by FTIR. Hence, the broad band observed from 3200 to 3550 cm
−1
 in the 
PVA spectra assigned to hydroxyls (νOH) stretching due to the strong hydrogen bond of 
intramolecular and intermolecular type [42-43]. Also, the strong band at 2870–2950 cm
−1
 
was attributed to alkyl stretching mode (νCH). The bands ranging from 1710 to 1750 
cm
−1
 and 1200 to 1275 cm
−1
 arise due to the stretching vibration of carbonyl (νC=O) and 
ester, respectively,  from the vinyl acetate group found in partially hydrolyzed PVA 
polymer . Some other bands which can be found related to PVA are located at 1410–1460 
cm−1 assigned to δ(CH)CH2; 1200–1270 cm−1 of group ν(C–O)–C–OH; 820–850 cm−1 
from alkyl chain
 
backbone [42-45]. In an analogous analysis, the FTIR spectrum of the 
SG-B presented the bands related to Si–O–Si asymmetric and symmetric stretching 
modes at approximately 1100 cm
−1
 and 800 cm
−1
, respectively [35–36]. There is an 
overlapping of the bands in the range from 900 to 1500 cm
−1
 derived from the bioactive 
glass and the PVA components [42-45]. It is worth noting that the composite formation 
leads to the broadening of the bands related to vinyl acetate copolymer, that almost 
disappear as a consequence of the hydrogen bonds involving C=O groups and silanol 
groups in silicate networks [48]. 
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3.3.1.2. X-ray diffraction analysis and FTIR after immersion in SBF 
The XRD of the prepared scaffolds after soaking in SBF for different time intervals 
demonstrated in figure (6). The calcium phosphate layer formed on the surface of 
PVA/SG-B is crystallized after three weeks of immersion in the SBF as documented 
before [49]. Indeed after 2 days of immersion, the peaks of crystallization related to the 
layer of HA formed on the surface of PVA/SG-B starts to appear and intensity increase 
progressively versus the time of immersion and SG-B content. After 21 days of soaking 
in SBF, the XRD pattern show rays with maximum at about 32
◦
. These peaks 
corresponding respectively to (211), (310) and (203) reticular plan and highlight the 
apatite like layer [49-51].  
Figure (7) The IR spectrum of synthetic hydroxyapatite is used as references to evaluate 
the structural evolution and the bioactivities of the prepared scaffolds.  After soaking in 
SBF solution, the initial characteristic bands of PVA/SG-B biocomposite are modified 
strongly because of the interfacial reactions scaffolds and the SBF. Consequently, the 
spectra of these biomaterials reveal new bands [51]. 
In detail, the spectrum of PVA/SG-B scaffold after 2 days of soaking in SBF shows three 
new well-defined phosphate bands at 565, 603 and 1039 cm
-1
. They are assigned to 
stretching vibrations of PO4
3-
 group in phosphate crystalline phases with low intensity 
due to great bounding affinity between SG-B and PVA due to this fact a relative slow 
reaction between PVA/SG-B scaffolds and SBF tacking place. This result confirms the 
formation of a calcium phosphate layer; this spectrum is quite similar to that of hydroxyl 
apatite except two bands located at 1620 and 3423 cm
-1
. These bands are characteristic of 
the presence of water related to the hygroscopic feature of the formed apatite. In addition, 
the carbonate band at 1420 cm
-1
 is also observed. This band attributes to a stretching 
vibration of the C-O liaisons in carbonate groups. The presence of carbonate bands 
indicates the formation of a layer of carbonated hydroxyapatite on the surface of 
PVA/SG-B biocomposite. The obtained results highlight the rapid formation of apatite 
layer on the surface of PVA/SG-B biocomposite. In addition, PVA/SG-B scaffolds reveal 
three Si-O-Si bands at 470 cm
-1
 (bending vibration), 799 cm
-1
 (bending vibration) and 
1075 cm
-1
 (stretch vibration). These confirm the presence of a silica gel [30]. The 
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appearance of apatite mineral and a silica gel indicate the interactions between the 
scaffolds and SBF as described by Hench et al. This mechanism could be explained 
through the following steps: 
(a) rapid exchange of protons H3O
+
 from the SBF with Ca
2+
 , Na
+
 ions in bioglass to form 
the Si-OH groups, (b) loss of soluble silica as Si(OH)
4
 by breaking of Si-O-Si bridging 
links and subsequent formation of surface silanol groups in the process, (c) condensation 
and repolymerization of surface silanols to form SiO2-rich surface layer, (d) migration of 
Ca
2+
 and PO4
3-
 through the surface silica-rich layer and formation of a Ca-P rich layer on 
the surface of biocomposite, (e) incorporation of OH
-
, CO3
2-
 from the solution and 
subsequent crystallization of the Ca-P layer to form HCA [53-56]. The obtained results 
confirm the bioactivity of PVA/BG biocomposite. Especially, they highlight the positive 
effect of SG-B particle size and SG-B bounding strength with PVA controls the 
formation rate of well crystallized apatite layer on its surface. 
 
3.2.2. SEM with EDS after immersion in SBF 
Two compositions of the prepared scaffolds have been under investigated by SEM 
coupled with EDS , figure (8), to evaluate their surface changes after soaking in SBF for 
21 days (PV and 1PVA:2SG-B). This scaffolds had exhibit excellent bioactivity and high 
fracture toughness. The hydroxy apatite crystals formed with condensed manure on the 
surface of the biocomposite scaffolds but the surface of PVA scaffold is not changed yet. 
Incorporation of PVA with SG-B induces a great modification to PVA bioactivity. SEM 
analysis suggested the excitants of strong molecular interaction between SG-B particles 
and PVA network, causing SG-B to be dispersed uniformly in the composite scaffolds. 
The presence of Ca, P, Na and Cl elements on the surface of the prepared composite 
scaffolds were determined by EDS. The phosphocalcic ratio Ca/P after 21 days of 
immersion in SBF is nearly equal to the stoichiometric apatite [33, 49 and 57-60].  
      
3.3.3. Evaluation of elemental concentrations in SBF 
The change of ions concentrations in SBF was demonstrated in figure (9). For P and Si 
ions they take the same behavior for all the prepared scaffolds with little difference in 
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their amount in the SBF. Which is due to the limit of the integrate combination between 
SG-B and PVA. This little difference is according to bounding and incorporation of SG-B 
into PVA. The SG-B particle size is affecting on the amount of P and Si in the SBF as its 
confirmed by XRD, FTIR and SEM with EDS. The ions concentration of Ca was found 
to be completely different for each composition of scaffolds. This is much believed to be 
according to the glass content in the scaffolds and the small particle size of SG-B as they 
in turn changes the porosity and the degradation rate in the SBF [35, 49, 50, 54, 57, 58, 
and 59]. 
 
3.4. Degradation   
Biodegradation rate of the prepared scaffolds was investigated in SBF at different time 
intervals with PVA alone as control as shown in figure (10). PVA scaffold exhibit higher 
degradation rate (100% after 2 days) than those of PVA/SG-B scaffolds. Ideally, in tissue 
engineering, a scaffold is usually intended to temporary fill a defect, while gradually 
degrading as neo-tissue is formed. In due course, the scaffold is replaced by new bone 
tissue [61]. After implantation, the scaffold interacts with the tissue fluids, uptaking them 
at some extent, starting the degradation process [62]. A relative low degradation rate is 
much favorable for cell attachment and differentiation. Furthermore, increases of the 
glass amount in the scaffold decreases the degradation rate due to the fact that 
incorporation of inorganic filler into polymer matrix decreases the porosity as confirmed 
by MIP and liquid displacement methods and as documented before [63 and 64]. Porosity 
decrease lead to decreases of the exposed surface area from the scaffold to the SBF. This 
decreasing prolong the consumed time for biodegradation, giving more time for cells 
attachment and proliferation [65].  
      
3.5. Ciprofloxacin incorporation 
The success of incorporation of ciprofloxacin into PVA and PVA/SG-B scaffolds was 
confirmed by XRD, FTIR and SEM coupled with EDS. 
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3.5.1. XRD  
Figures (11.1) represent the XRD for PVA and PVA/SG-B scaffolds with and without the 
drug. Ciprofloxacin has specific sharp crystal peaks while PVA, SG-B and PVA/SG-B 
have broad peaks. When ciprofloxacin was entrapped into the scaffold matrix, its sharp 
crystal peaks were overlapped with the noise of the surrounded polymer and disappeared 
indicating that ciprofloxacin was successfully entrapped into the scaffold matrix system 
and formation of a new solid phase for ciprofloxacin with low crystallinity[66-70]. 
 
3.5.2. FTIR 
The FTIR for ciprofloxacin loaded scaffolds are demonstrated in figures (11.2). The 
FTIR spectrum of ciprofloxacin shows one prominent characteristic band between 3500 
and 3450 cm
-1
, which was assigned to stretching vibration of OH groups Another band at 
3000- 2950 cm
-1
 represent alkene and aromatic C-H stretching, mainly υ=C-H was 
demonstrated. The 1950 to 1450 cm
-1
 region exhibited FTIR absorption from a wide 
variety of double-bonded functional groups. The band at 1750 to 1700 cm
-1
 represented 
the carbonyl C=O stretching i.e., υC=O. The peak between 1650 and 1600 cm -1 was 
assigned to quinolones. The band from 1450 to 1400 cm
-1
 represented υC-O and at 1300 
to 1250 cm
-1
 suggested bending vibration of O-H group which proved the presence of 
carboxylic acid. A strong absorption band between 1050 and 1000cm
-1
 was assigned to 
C-F group. The FTIR for the PVA scaffolds loaded with ciprofloxacin indicate the 
presence of new bands at 3522, 1744, and 1473.52 cm
-1
 when compared with those of 
non-medicated scaffold due to the presence of ciprofloxacin. These bands were indicated 
also for PVA/SG-B scaffolds loaded with ciprofloxacin beside another band at 1088 cm
-1 
with high intensity due to combination of drug with glass particles into the polymer 
matrix. A shorter band appeared in the region of 1500–1200 cm
-1 
that could be ascribed 
to the hydrated bonds with ciprofloxacin molecules [66-73]. 
The FTIR spectra indicate that, although a physical interaction between the drug and the 
scaffold components occurs with both PVA/SG-B scaffolds. This is probably because 
PVA/SG-B has a greater content of pendant hydroxyl groups that are more accessible for 
establishing hydrogen bonds with the drug [69].  
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3.5.3. SEM coupled with EDS 
The SEM image of the drug shows rod shape crystals and its EDS indicate the presence 
of F and Cl elements which are the main components of the drug as demonstrated in 
figure (11.3). SEM images for the cross-section of scaffold loaded with the ciprofloxacin 
reveal the rod shape of ciprofloxacin crystal in the scaffold matrix system [70, 75]Also 
the EDS confirm the presence of F and Cl elements in the scaffolds loaded with 
ciprofloxacin . Therefore, XRD, FTIR and SEM coupled with EDS indicate and confirm 
the success incorporation of ciprofloxacin into PVA and PVA/SG-B scaffolds. 
 
3.6 Release behavior of ciprofloxacin 
The release behavior of ciprofloxacin from the prepared scaffolds is presented in figure 
(12). Considering the hydrophilic molecule, ciprofloxacin is expected to exhibit burst 
release from the investigated system. Moreover, a sustained drug release profile was 
observed form the investigated figures with quasi-Fickian diffusion mechanism (n-values 
less than 0.5).  This mechanism indicates that the polymer is hydrated, swell and then the 
drug diffuses through the swollen matrix system, which ultimately slows down the 
kinetic release. 
The release profile for ciprofloxacin from scaffold prepared from PVA/SG-B loaded with 
5, 10 and 20% ciprofloxacin was higher than that for scaffold loaded with PVA scaffolds 
loaded with 5, 10 and 20% of ciprofloxacin. This could be due to the interaction between 
PVA alone with ciprofloxacin resulting in great bounding affinity between the drug and 
PVA polymer. On the other hand presence of SG-B particles in the polymer matrix leaves 
no free space for the ciprofloxacin causing fast release for the drug in the PBS. [67, 71 
and 75].     
16 
 
Conclusions 
In this study, the PVA/SG-B biocomposite scaffolds loaded with ciprofloxacin with well 
interconnected pore structure were fabricated via freeze drying technique. The 
degradation rate and physicochemical properties of the prepared scaffold by freeze drying 
for tissue engineering could be controlled by controlling glass content and drug 
concentrations. The pore size achieved is suitable for cell activation and tissue 
regeneration. Drug loaded scaffolds with ciprofloxacin exhibit a good drug delivery 
system with sustained drug release. The biodegradation rate and structural morphology of 
the prepared scaffolds could be controlled by adjusting ciprofloxacin percentage.  
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Table 
 
Table (1): porosity percentage and pore diameter measured by mercury Hg porosimeter and 
liquid displacement techniques.     
  
Porosity % pore 
diameter 
range (4V/A) 
Liquid displacement 
With drug 
20% 10% 5% 
Without drug 
MIP nm  µm  
Sample name  
66 69 72 85.47 88.14  6.2  139  PVA 
73 74 77 79.46 74.95 6.3 131 2PVA:1SG‐B 
67 69 70 70.30 67.60 6.3 119 1PVA:1SG‐B 
55 58 59 60.50 46.68 6.3 110 1PVA:2SG‐B 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Freezing at ‐ 18оC for overnight  
The resulted mixture was casted in Teflon molds. 
Addition of BG on the dissolved PVA continues stirring for overnight.
Drug addition on the above mixture continues stirring for 1 hr. 
PVA dissolving in distilled water at 80 оC with 15% W/V. 
Lyophilization at ‐56оC for 24 hr.  
Figure (1.1) 
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Figure (1.2) TEM image of the prepared glass  
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Figure (2) SEM images of a)PVA scaffold , b) PVA scaffold loaded with 20% 
ciprofloxacin , c) 1PVA:2SG‐B  and d) 1PVA:2SG‐B scaffold loaded with 20% 
ciprofloxacin  
27 
 
 
Figure (3) compressive strength of prepared scaffolds   
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Figure (4) XRD of the prepared scaffolds before immersion in SBF 
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Figure (5) FTIR of the prepared scaffolds before immersion in SBF 
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Figure (6.1) XRD of 2PVA:1SG‐B after soaking in SBF 
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Figure (6.2) 1PVA:1SG‐B after soaking in SBF
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Figure (6.3) 1PVA:2SG‐B after soaking in SBF 
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Figure (7.1) 2PVA:1SG‐B after soaking in SBF 
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Figure (7.2) 1PVA:1SG‐B after soaking in SBF 
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Figure (7.3) 1PVA:2SG‐B after soaking in SBF 
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Figure (8.1)  SEM with EDS of PVA scaffold after 21 days of immersion in SBF 
   
Figure (8.2)  SEM with EDS of 1PVA:2SG-B scaffold after 21 days of immersion in SBF 
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Figure (9.1) Ca ions concentrations after soaking of the prepared Scaffolds in SBF for 
different times intervals 
 
Figure (9.2) P ions concentrations after soaking of the prepared Scaffolds in SBF for 
different times intervals 
 
Figure (9.3) Si ions concentrations after soaking of PVA Scaffolds in SBF for different 
times intervals 
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Figure (10) biodegradation rate of the prepared scaffold with and without drug 
in PBS 
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Figure (11.1) XRD of the prepared scaffolds before and after drug incorporation  
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Figure (11.2) FTIR of the prepared scaffolds before and after drug incorporation 
37 
 
 
Figure (11.3) SEM with EDS of a) ciprofloxacin , b) PVA scaffold 
loaded with 20% ciprofloxacin and c) 1PVA:2SG-B scaffold loaded 
with 20% ciprofloxacin   
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Figure (12.1) cumulative ciprofloxacin release from PVA scaffolds in PBS 
 
Figure (12.1) cumulative ciprofloxacin release from 1PVA:2SG‐B scaffolds in PBS 
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